LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

167.49 -5.29

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

166.9

Massimo

176.76

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

EPS

2.43

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+15.43% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

772M

8.7B

Apertura precedente

172.78

Chiusura precedente

167.49

Notizie sul Sentiment di mercato

By Acuity

27%

73%

52 / 351 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 mar 2026, 20:38 UTC

Utili

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mar 2026, 23:57 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

10 mar 2026, 23:57 UTC

Discorsi di Mercato

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mar 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mar 2026, 23:37 UTC

Acquisizioni, Fusioni, Takeovers

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mar 2026, 23:37 UTC

Acquisizioni, Fusioni, Takeovers

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mar 2026, 23:37 UTC

Acquisizioni, Fusioni, Takeovers

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mar 2026, 23:37 UTC

Acquisizioni, Fusioni, Takeovers

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mar 2026, 23:35 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mar 2026, 23:06 UTC

Utili

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mar 2026, 22:51 UTC

Principali Notizie su Eventi

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mar 2026, 21:39 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mar 2026, 21:21 UTC

Utili

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mar 2026, 21:15 UTC

Utili

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mar 2026, 21:15 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mar 2026, 21:14 UTC

Utili

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mar 2026, 21:13 UTC

Utili

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mar 2026, 21:12 UTC

Utili

Franco-Nevada 4Q Rev $597.3M >FNV

10 mar 2026, 21:12 UTC

Utili

Franco-Nevada 4Q EPS $1.90

10 mar 2026, 20:57 UTC

Utili

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

10 mar 2026, 20:44 UTC

Utili

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:34 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

10 mar 2026, 20:34 UTC

Discorsi di Mercato
Utili

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mar 2026, 20:23 UTC

Utili

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:16 UTC

Utili

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mar 2026, 20:14 UTC

Utili

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mar 2026, 20:14 UTC

Utili

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mar 2026, 20:13 UTC

Utili

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mar 2026, 20:12 UTC

Utili

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

15.43% in crescita

Previsioni per 12 mesi

Media 204.3 USD  15.43%

Alto 265 USD

Basso 175 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

8

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

52 / 351 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat